S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by monoclonal antibody therapy in treating patients who have newly diagnosed follicular non... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Beckman Research Institute, City of Hope, Duarte, California +10 locations
Conditions: Lymphoma
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Antiviral therapy may be effective treatment for AIDS-related lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and antiviral therapy in treating patients who have AIDS-related lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2013
Locations: Veterans Affairs Medical Center - Long Beach, Long Beach, California +9 locations
Conditions: Lymphoma
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
Completed
RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, or combination chemotherapy, which uses different ways to stop tumor cells from dividing so they stop growing or die, may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of reducing immunosuppression, and giving interferon alfa and combination chem... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
01/22/2013
Locations: Veterans Affairs Medical Center - Long Beach, Long Beach, California +8 locations
Conditions: Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide, methotrexate, and fluorouracil in treating patients with Merkel cell cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: Veterans Affairs Medical Center - Long Beach, Long Beach, California +9 locations
Conditions: Neuroendocrine Carcinoma of the Skin
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
Completed
This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in maintaining remission and renal function. Patients were randomized to receive either MMF (1.5 g twice daily \[bid\]) or cyclophosphamide (0.5-1.0 g/m\^2 in monthly pulses) in the induction phase. Those patients meeting criteria for response were re-randomized for entry in... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
10/31/2011
Locations: Not set, La Jolla, California +4 locations
Conditions: Lupus Nephritis
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Completed
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/03/2011
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +4 locations
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation plus combination chemotherapy in treating patients who have hematologic cancer or nonmalignant hematologic disease.
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/31/2010
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +3 locations
Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given before or after surgery for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy using doxorubicin and cyclophosphamide with or without docetaxel in treating women who have stage II or stage III breast cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/02/2010
Locations: Sutter Health Western Division Cancer Research Group, Greenbrae, California +10 locations
Conditions: Breast Cancer
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
Unknown
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with cyclophosphamide, dexamethasone, and thalidomide may kill more cancer cell... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2009
Locations: Alta Bates Summit Comprehensive Cancer Center, Berkeley, California +3 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Unknown
This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2005
Locations: East Valley Hematology and Oncology Medical Group, Burbank, California +10 locations
Conditions: Chronic Lymphocytic Leukemia
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
Completed
OBJECTIVES: I. Evaluate the efficacy of related, HLA-identical bone marrow transplantation following cyclophosphamide (CTX) and antithymocyte globulin in patients with aplastic anemia. II. Evaluate the efficacy of related, HLA-nonidentical bone marrow transplantation following CTX and total-body irradiation/total-lymphoid irradiation in patients with aplastic anemia.
Gender:
ALL
Ages:
Between 0 years and 55 years
Trial Updated:
06/23/2005
Locations: Center for Health Sciences, Los Angeles, California
Conditions: Aplastic Anemia